High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation

Cancer Letters

Volumn 369, Issue 2, 2015, Pages 363-367

  Gorodnova, Tatiana V ^a   Sokolenko, Anna P ^a,b   Ivantsov, Alexandr O ^a,b   Iyevleva, Aglaya G ^a,b   Suspitsin, Evgeny N ^a,b   Aleksakhina, Svetlana N ^a   Yanus, Grigory A ^a,b   Togo, Alexandr V ^a,b   Maximov, Sergey Ya ^a   Imyanitov, Evgeny N ^a,b,c,d  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

^c NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^d ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

Author keywords

BRCA1; Loss of heterozygosity (LOH); Neoadjuvant therapy; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL;

ADULT; AGED; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CHEMOSENSITIVITY; DRUG RESPONSE; FEMALE; GENE MUTATION; GENOTYPE; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WILD TYPE; ADJUVANT THERAPY; GENETICS; MIDDLE AGED; OVARIAN NEOPLASMS; PROCEDURES;

ADULT; AGED; FEMALE; GENES, BRCA1; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS;

EID: 84945460110     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.08.028     Document Type: Article

References (52)

1. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med 2004, 351(24):2519-2529.
2. Suspitsin E.N., Sherina N.Y., Ponomariova D.N., Sokolenko A.P., Iyevleva A.G., Gorodnova T.V., et al. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. Hered. Cancer Clin. Pract 2009, 7(1):5.
3. Alsop K., Fereday S., Meldrum C., deFazio A., Emmanuel C., George J., et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol 2012, 30(21):2654-2663.
4. Bast R.C., Mills G.B. Personalizing therapy for ovarian cancer: BRCAness and beyond. J. Clin. Oncol 2010, 28(22):3545-3548.
5. Hennessy B.T., Timms K.M., Carey M.S., Gutin A., Meyer L.A., Flake D.D., et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J. Clin. Oncol 2010, 28(22):3570-3576.
6. Tropé C.G., Elstrand M.B., Sandstad B., Davidson B., Oksefjell H. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?. Eur. J. Cancer 2012, 48(14):2146-2154.
7. Cass I., Baldwin R.L., Varkey T., Moslehi R., Narod S.A., Karlan B.Y. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97(9):2187-2195.
8. Tan D.S., Rothermundt C., Thomas K., Bancroft E., Eeles R., Shanley S., et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol 2008, 26(34):5530-5536.
9. Adams S.F., Marsh E.B., Elmasri W., Halberstadt S., Vandecker S., Sammel M.D., et al. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol. Oncol 2011, 123(3):486-491.
10. Imyanitov E.N., Moiseyenko V.M. Drug therapy for hereditary cancers. Hered. Cancer Clin. Pract 2011, 9(1):5.
11. Safra T., Borgato L., Nicoletto M.O., Rolnitzky L., Pelles-Avraham S., Geva R., et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol. Cancer Ther 2011, 10(10):2000-2007.
12. Vencken P.M., Kriege M., Hoogwerf D., Beugelink S., van der Burg M.E., Hooning M.J., et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann. Oncol 2011, 22(6):1346-1352.
13. Kwa M., Edwards S., Downey A., Reich E., Wallach R., Curtin J., et al. Ovarian cancer in BRCA Mutation carriers: improved outcome after intraperitoneal (IP) cisplatin. Ann. Surg. Oncol 2014, 21(5):1468-1473.
14. Safra T., Rogowski O., Muggia F.M. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int. J. Gynecol. Cancer 2014, 24(3):488-495.
15. Sun C., Li N., Ding D., Weng D., Meng L., Chen G., et al. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PLoS ONE 2014, 9(5):e95285.
16. Moiseyenko V.M., Chubenko V.A., Moiseyenko F.V., Zhabina A.S., Gorodnova T.V., Komarov Y.I., et al. Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. Med. Oncol 2014, 31(10):199.
17. Sokolenko A.P., Iyevleva A.G., Mitiushkina N.V., Suspitsin E.N., Preobrazhenskaya V., Kuligina E.S., et al. Hereditary breast-ovarian cancer syndrome in Russia. Acta Nat 2010, 2(4):31-35.
18. Bardia A., Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin. Cancer Res 2013, 19(23):6360-6370.
19. Kehoe S., Hook J., Nankivell M., Jayson G.C., Kitchener H., Lopes T., et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015, 386(9990):249-257. 10.1016/S0140-6736(14)62223-6.
20. Mitiushkina N.V., Iyevleva A.G., Poltoratskiy A.N., Ivantsov A.O., Togo A.V., Polyakov I.S., et al. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol 2013, 121(7):370-376.
21. Sokolenko A.P., Bogdanova N., Kluzniak W., Preobrazhenskaya E.V., Kuligina E.S., Iyevleva A.G., et al. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. Breast Cancer Res. Treat 2014, 145(2):553-562.
22. Suspitsin E.N., Yanus G.A., Sokolenko A.P., Yatsuk O.S., Zaitseva O.A., Bessonov A.A., et al. Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele. Med. Oncol 2014, 31(2):828.
23. Moiseyenko V.M., Volkov N.M., Suspistin E.N., Yanus G.A., Iyevleva A.G., Kuligina E.S., et al. Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer. Med. Oncol 2013, 30(2):545.
24. Sassen S., Schmalfeldt B., Avril N., Kuhn W., Busch R., Höfler H., et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum. Pathol 2007, 38(6):926-934.
25. King T.A., Li W., Brogi E., Yee C.J., Gemignani M.L., Olvera N., et al. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann. Surg. Oncol 2007, 14(9):2510-2518.
26. Swisher E.M., Sakai W., Karlan B.Y., Wurz K., Urban N., Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008, 68(8):2581-2586.
27. Brozek I., Ochman K., Debniak J., Morzuch L., Ratajska M., Stepnowska M., et al. Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers. J. Appl. Genet 2009, 50(4):379-384.
28. Norquist B., Wurz K.A., Pennil C.C., Garcia R., Gross J., Sakai W., et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol 2011, 29(22):3008-3015.
29. Patch A.M., Christie E.L., Etemadmoghadam D., Garsed D.W., George J., Fereday S., et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015, 521(7553):489-494.
30. Coleman R.L., Sill M.W., Bell-McGuinn K., Aghajanian C., Gray H.J., Tewari K.S., et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG Oncology/Gynecologic Oncology Group study. Gynecol. Oncol 2015, 137(3):386-391.
31. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med 2009, 361(2):123-134.
32. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376(9737):245-251.
33. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med 2012, 366(15):1382-1392.
34. Vergote I., Amant F., Leunen K. Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?. Gynecol. Oncol 2010, 119(1):1-2.
35. Weinberg L.E., Rodriguez G., Hurteau J.A. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J. Surg. Oncol 2010, 101(4):334-343.
36. Chi D.S., Bristow R.E., Armstrong D.K., Karlan B.Y. Is the easier way ever the better way?. J. Clin. Oncol 2011, 29(31):4073-4075.
37. Di Giorgio A., Sammartino P., Biacchi D. Neoadjuvant chemotherapy fails to improve survival in advanced ovarian cancer: but is it the real culprit?. Int. J. Gynecol. Cancer 2011, 21(4):596.
38. Marth C., Zeimet A., Du Bois A. Is neoadjuvant chemotherapy in ovarian cancer an excuse for insufficient surgery?. Oncology (Williston Park) 2011, 25(10):940. 942, 944.
39. Onda T., Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions. Expert Rev. Anticancer Ther 2011, 11(7):1053-1067.
40. du Bois A., Marth C., Pfisterer J., Harter P., Hilpert F., Zeimet A.G., et al. Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer. Int. J. Gynecol. Cancer 2012, 22(2):182-185.
41. Vergote I., Leunen K., Amant F. Primary surgery or neoadjuvant chemotherapy in ovarian cancer: what is the value of comparing apples with oranges?. Gynecol. Oncol 2012, 124(1):1-2.
42. Schorge J.O., Clark R.M., Lee S.I., Penson R.T. Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter?. Gynecol. Oncol 2014, 135(3):595-605.
43. Vergote I., Tropé C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med 2010, 363(10):943-953.
44. Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol. Oncol 2006, 103(3):1070-1076.
45. Taşkin S., Güngör M., Ortaç F., Öztuna D. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer. Arch. Gynecol. Obstet 2013, 288(6):1399-1403.
46. Naik R., Barton D.P. Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancer. N. Engl. J. Med 2010, 363(24):2370-2371.
47. Kang S. Neoadjuvant chemotherapy for ovarian cancer: do we have enough evidence?. Lancet 2015, 386(9990):223-224.
48. Morrison J., Haldar K., Kehoe S., Lawrie T.A. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst. Rev 2012, (8). CD005343.
49. Vergote I., du Bois A., Amant F., Heitz F., Leunen K., Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree?. Gynecol. Oncol 2013, 128(1):6-11.
50. Kang S., Nam B.H. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann. Surg. Oncol 2009, 16(8):2315-2320.
51. Milam M.R., Harrell R., Bassett R., Parker L.P., Metzinger D.S., Ramirez P.T. Clinical characteristics of patients with prolonged disease-free survival after primary treatment in advanced ovarian cancer: a brief report. Int. J. Gynecol. Cancer 2011, 21(3):475-477.
52. Muraji M., Sudo T., Iwasaki S., Ueno S., Wakahashi S., Yamaguchi S., et al. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery. Gynecol. Oncol 2013, 131(3):531-534.